Home' Australian Pharmacist : Australian Pharmacist February 2012 Contents 146 Australian Pharmacist February 2012 I ©Pharmaceutical Society of Australia Ltd.
Continuing Professional Development
The articles in this series are independently researched and compiled by PSA commissioned authors and peer reviewed.
EVIDENCE IN PATIENT CARE
Submit your answers online before
1 April 2012 at www.psa.org.au
and receive automatic feedback, or
PSA CPD answers
Pharmaceutical Society of Australia,
Level 1, 381 Royal Parade,
PARKVILLE VIC 3052
Fax: (03) 9389 4044
NZCP CPD answers,
PO Box 11 640,
Fax: (04) 381 4786
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of
PSA's CPD&PI program. It is also part of the New
Zealand College of Pharmacists (NZCP) education
program for NZ pharmacists.
The CPD section is recognised under the PSA
CPD&PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer. The credits allocated to
each section and the pass mark are shown with
CPD credits are allocated as follows: a minimum
of 6 out of 8 questions correct attracts 1.5 credits,
a minimum of 4 out of 5 questions correct
attracts 1 credit, and a minimum of 3 out of
4 questions correct attracts three quarters of
If not submitting online, write the correct
answers in the spaces provided on the answer
panel on the back of the address sheet, fill in your
name, member number and address details, then
either mail or fax the answer page to the relevant
address and fax number for marking.
PSA members can answer online at
www.psa.org.au and receive automatic
• You will need to login to submit your answers
online. If you do not have member access
details, you can request them via a link from
the login page.
• Select Pharmacist Members from the blue, left
hand side menu.
• Select Submit Answers.
• Select Australian Pharmacist CPD.
If live lice are found the day following
initial treatment, another option should be
chosen. Alternatives include using another
insecticide (first-line), the wet combing
method (second-line) or heat treatment
(third-line). Failing these strategies,
prescription options such as co-trimoxazole
or ivermectin are indicated. The conditioner
and comb method should be repeated
weekly for several weeks after cure to
1. Counahan M, et al. Head lice prevalence in primary schools
in Victoria, Australia. Journal of paediatrics and child health
2. Speare R, et al. Head lice are not found on floors in primary
school classrooms. Australian and New Zealand Journal of
Public Health 2002;26(3):208--11.
3. Roberts RJ. Clinical practice. Head lice. New Engl J Med
4. Elston DM. Drugs used in the treatment of pediculosis. Journal
of drugs in dermatology : JDD 2005;4(2):207--11.
5. Mumcuoglu KY, et al. Clinical observations related to head lice
infestation. Journal of the American Academy of Dermatology
1991;25(2 Pt 1):248--51.
6. Burgess IF. Human lice and their management. Advances in
7. Chunge RN, et al. A pilot study to investigate transmission of
headlice. Canadian journal of public health. Revue canadienne
de sante publique 1991;82(3):207--08.
8. Frankowski BL, Bocchini JA, Jr. Head lice. Pediatrics
9. Speare R, et al. Head lice on pillows, and strategies to make
a small risk even less. International journal of dermatology
10. Pollack RJ, et al. Overdiagnosis and consequent
mismanagement of head louse infestations in North America.
The Pediatric infectious disease journal 2000;19(8):689--93;
11. Meinking TL, et al. Comparative in vitro pediculicidal efficacy
of treatments in a resistant head lice population in the United
States. Archives of dermatology 2002;138(2):220--4.
12. Lebwohl M, et al. Therapy for head lice based on life
cycle, resistance, and safety considerations. Pediatrics
13. Mumcuoglu KY, et al. Permethrin resistance in the head
louse Pediculus capitis from Israel. Medical and veterinary
entomology 1995;9(4):427--32, 447.
14. James S. A review of the regulation of head lice treatments
in Australia. Canberra: Medicines Evaluation Committee,
Therapeutic Goods Administration; 2003.
15. Australian Medicines Handbook. Adelaide: Australian Medicines
16. Rasmussen JE. Pediculosis: treatment and resistance. Advances
in dermatology 1986;(1):109--25.
17. Burkhart CG. Relationship of treatment-resistant head lice to the
safety and efficacy of pediculicides. Mayo Clinic proceedings.
Mayo Clinic 2004;79(5):661--6.
18. Therapeutic Guidelines. eTG Complete: Dermatology; 2011.
19. Burgess IF, et al. Treatment of head louse infestation with 4%
dimeticone lotion: randomised controlled equivalence trial. BMJ
20. Kaul N, et al. North American efficacy and safety of a novel
pediculicide rinse, isopropyl myristate 50% (Resultz). Journal of
cutaneous medicine and surgery 2007;11(5):161--7.
21. Greive KA, et al. A randomised, double-blind, comparative
efficacy trial of three head lice treatment options: malathion,
pyrethrins with piperonyl butoxide and MOOV Head Lice
Solution. Aust Pharmacist 2007;26(9):738--43.
22. Goates BM, et al. An effective nonchemical treatment for head
lice: a lot of hot air. Pediatrics 2006;118(5):1962--70.
1. The prevalence of head lice in
Australian school children is thought
to be in the order of:
b) 5% to 12%.
c) 13% to 21%.
d) 25% to 35%.
2. Head lice cause itching in
approximately what proportion of
a) 0% to 15%.
b) 15% to 30%.
c) 30% to 45%.
3. Which of the following is the
LEAST likely to be responsible for
transmission of head lice?
b) Sharing of combs.
4. Which ONE of the following is NOT a
a) Benzyl alcohol.
d) Isopropyl myristate.
5. Resistance of head lice has been
demonstrated for each of the
a) Benzyl alcohol.
A score of 4 out of 5 attracts 1 CPD credit.
Links Archive Australian Pharmacist March 2012 Australian Pharmacist January 2012 Navigation Previous Page Next Page